Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 295.60
+13.05 (4.62%)
Mar 10, 2026, 3:29 PM IST
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 108.09 billion as of March 10, 2026. Its market cap has decreased by -61.03% in one year.
Market Cap
108.09B
Enterprise Value
109.97B
Revenue
10.79B
Ranking
n/a
PE Ratio
120.25
Stock Price
295.60
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 108.09B, an increase of 320,607.15%. That is a compound annual growth rate of 283.78%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 9, 2026 | 108.09B | -46.55% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Emcure Pharmaceuticals | 288.38B |
| Gland Pharma | 276.38B |
| Wockhardt | 206.24B |
| Piramal Pharma | 201.04B |
| Eris Lifesciences | 188.49B |
| NATCO Pharma | 179.59B |
| Alembic Pharmaceuticals | 139.26B |
| Alivus Life Sciences | 112.31B |